News & Media

August 26, 2024

NEWS RELEASE: WEX PHARMACEUTICALS INC. ANNOUNCES FAST TRACK DESIGNATION GRANTED BY THE FDA FOR HALNEURON® (TETRODOTOXIN FOR INJECTION) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN

Read more
August 20, 2024

NEWS RELEASE: WEX PHARMACEUTICALS INC. FILES US PATENT APPLICATION FOR USE OF TETRODOTOXIN IN OCULAR APPLICATIONS

Read more
August 7, 2024

NEWS RELEASE: WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN 2024 WORLD CONGRESS ON PAIN, ON ITS LEAD COMPOUND HALNEURON®

Read more
July 24, 2024

NEWS RELEASE: WEX PHARMACEUTICALS INC. FILES A PATENT APPLICATION FOR ITS MANUFACTURING PROCESS TO SYNTHESIZE A KEY INTERMEDIATE OF TETRODOTOXIN

Read more
July 18, 2024

NEWS RELEASE WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT THE IASP 2024 WORLD CONGRESS ON PAIN

Read more
December 11, 2023

NEWS RELEASE: WEX PHARMACEUTICALS INC. COMMENCES ITS QUANTITATIVE SENSORY TESTING CLINICAL TRIAL EVALUATING THE IMPACT OF HALNEURON® ON HEALTHY VOLUNTEERS’ SENSORY PERCEPTIONS

Read more
September 25, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®)

Read more
September 12, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®

Read more
1 2 3